Savior Lifetec Corporation

Taipei Exchange 4167.TWO

Savior Lifetec Corporation Price to Earnings Ratio (P/E) on January 14, 2025: 195.56

Savior Lifetec Corporation Price to Earnings Ratio (P/E) is 195.56 on January 14, 2025, a -6.74% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Savior Lifetec Corporation 52-week high Price to Earnings Ratio (P/E) is 6,421.73 on December 20, 2024, which is 3,183.81% above the current Price to Earnings Ratio (P/E).
Savior Lifetec Corporation 52-week low Price to Earnings Ratio (P/E) is 177.99 on March 15, 2024, which is -8.98% below the current Price to Earnings Ratio (P/E).
Savior Lifetec Corporation average Price to Earnings Ratio (P/E) for the last 52 weeks is 234.06.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Taipei Exchange: 4167.TWO

Savior Lifetec Corporation

CEO	Mr. Chih-Fang Chen
IPO Date	Dec. 21, 2012
Location	Taiwan
Headquarters	29, Ke-Jhong Road
Employees	384
Sector	Health Care
Industries Pharmaceuticals

Description

Savior Lifetec Corporation, a specialty injectable company, produces and supplies sterile APIs and finished dosage formulations. The company offers imipenem and cilastatin sodium, an antibacterial agent for intravenous infusion; and meropenem, a beta-lactamase resistant carbapenem antibiotic for parenteral administration. It also provides ertapenem, a form of carbapenem for use on gram-negative and gram-positive anaerobes and aerobic. The company's pipeline products include SLC-006 for prostate cancer endometriosis uterine leiomyoma; and sterile paliperidone palmitate API for the treatment of schizophrenia. Savior Lifetec Corporation was founded in 2004 and is headquartered in Miaoli County, Taiwan.

Key trends

Past 5 years